

Thiocyanate promoted difunctionalization and cyclization of unsaturated C-C bonds to construct 1-sulfur-2-nitrogen- functionalized alkenes and 2-thiocyanate indolines

Hong Qin^a, Feng Chen^a, Jinze Du^a, Xiaobing Yang^b, Yiping Huang^c, Kai Zhu^c, Changhai Yue^c, Zheng Fang^{*a,d}, Kai Guo^{a,d}

^a*Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, 30 Puzhu Rd S., Nanjing, China, 211816.*

^b*Institute of Nanjing Advanced Biomaterials & Processing Equipment, Nanjing, P. R. China, 210031.*

^c*China Construction Industrial & Energy Engineering Group, Nanjing 210023, China.*

^d*State Key Laboratory of Materials-Oriented Chemical Engineering, 30 Puzhu Rd S., Nanjing, China, 211816.*

Table of Contents


1. General Information	2
2. Experimental section	2
2.1 General Procedure for the synthesis of starting materials	2
2.2 General Procedure for the synthesis of product 3 and product 5	3
2.3 Gram-scale synthesis of 3a	4
2.4 General Procedure for the synthesis of product 7	5
2.5 Characterization data	5
3. References	17
4. ¹H NMR, ¹⁹F NMR and ¹³C NMR spectra	18

1. General Information


Unless otherwise indicated, all commercially available chemicals were used without purification. ^1H NMR (400 MHz), ^{13}C NMR (100 MHz) and ^{19}F NMR (376 MHz) were measured on 400 M spectrometer. The chemical shifts are given in parts per million (ppm) on the delta (δ) scale. ^1H NMR chemical shifts were determined relative to internal TMS at δ 0.0 ppm. ^{13}C NMR chemical shifts were determined relative to CDCl_3 at δ 77.00 ppm. The following abbreviations were used to explain multiplicities: s = singlet, d = doublet, dd = doublet of doublet, t = triplet, td = triplet of doublet, q = quartet, m = multiplet, and br = broad. Analytical TLC was performed on 0.2 mm coated silica gel plates and visualized the course of the reactions using a UV light 254 nm. High-resolution mass spectra (HRMS) were obtained on an Agilent mass spectrometer using ESI-TOF (electrospray ionization-time of flight).

2. Experimental section

2.1 General Procedure for the synthesis of starting materials¹⁻⁴




In an oven-dried flash (100 mL), the solution of aniline (465.7 mg, 5 mmol) in DCM (6 mL) were added pyridine (791 mg, 10 mmol) and TsCl (1.91 g, 10 mmol). The resulting solution was stirred for 2 h. Then the mixture was quenched with saturated NH₄Cl solution, extracted with DCM. The combined organic layers were washed with water, dried over anhydrous NaSO₄ and filtered. The organic solvent was evaporated under the reduced pressure and the residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 5/1) to afford the desired product in quantitative yield (1.237 g) as a white solid.



In an oven-dried flash (100 mL), to a solution of terminal alkynes (3.0 mmol) in acetone (10 mL) were added NBS (3.6 mmol) and AgNO₃ (0.15 mmol), the resulting mixture was stirred under N₂ at room temperature for 3 hours. After removing excess acetone, the reaction

was quenched with saturated NH_4Cl solution, and the organic layer was extracted with petroleum ether ($10\text{ mL}\times 2$), dried over anhydrous NaSO_4 , filtered and concentrated under reduced pressure to give bromoalkynes.




To a dried flask were added sulfonamides (12.0 mmol), $\text{CuSO}_4\cdot 5\text{H}_2\text{O}$ (1.0 mmol), 1,10-phenanthroline (2.0 mmol) and K_2CO_3 (25.0 mmol). The resulting mixture was subsequently treated with anhydrous toluene (50 mL) and bromoalkynes (10.0 mmol), and stirred at $80\text{ }^\circ\text{C}$ overnight under N_2 . When the reaction mixture was cooled to room temperature, to the reaction mixture was added H_2O (50 mL), with subsequent extraction with CH_2Cl_2 ($50\text{ mL}\times 3$). The organic layer was dried over Na_2SO_4 . After the filtration and evaporation of the solvents under reduced pressure, the crude product was purified by column chromatography on silica gel using *n*-hexane as eluent.




Copper iodide (1.0 mmol, 0.2 equiv), cesium carbonate (10.0 mmol, 2.0 equiv), and aniline analogs (5.0 mmol, 1.0 equiv) were first added sequentially to a 100 mL flask, and then displaced by three successive vacuum-argon cycles. The solvent THF (50 mL) was then added, followed by *N,N'*-dimethylethylenediamine (2.0 mmol, 0.4 equiv) and β -bromostyrene (11 mmol, 1.1 equiv). The mixture was then heated to reflux for 3 h at $80\text{ }^\circ\text{C}$ (monitored by TLC). After cooling to room temperature, water (20 mL) was added to the reaction mixture, which was subsequently extracted with ethyl acetate ($50\text{ mL}\times 3$), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was separated by silica gel column chromatography using *n*-hexane/ EtOAc (25:1) as eluent to finally obtain the target compound.

2.2 General Procedure for the synthesis of product 3 and product 5




A 20 mL vial was charged with substrate **1** (0.1 mmol, 1.0 equiv), **2a** (2.0 equiv), PIDA (1.5 equiv), CH₃COOH (1.5 equiv), 1,1-Dichloroethane (DCE, 2 mL) and a magnetic stir bar. The reaction mixture was reacted at 30 °C for 12 hours. After completing reaction, it was monitored with TLC. Then the reaction mixture was diluted with EtOAc (10 mL) and filtered through a pad of silica gel. The vial and silica gel were washed with an additional of EtOAc (20 mL). The filtrate was concentrated *in vacuo*, and the resulting residue was purified by flash column chromatography using EtOAc /*n*-hexane as the eluent to afford the product.



A 20 mL vial was charged with substrate **1b** (0.1 mmol, 1.0 equiv), **2a** (2.0 equiv), PIDA (1.5 equiv), CH₃COOH (1.5 equiv), 1,1-Dichloroethane (DCE, 2 mL) and a magnetic stir bar. The reaction mixture was reacted at 30 °C for 12 hours. After completing reaction, it was monitored with TLC. Then the reaction mixture was diluted with EtOAc (10 mL) and filtered through a pad of silica gel. The vial and silica gel were washed with an additional of EtOAc (20 mL). The filtrate was concentrated *in vacuo*, and the resulting residue was purified by flash column chromatography using EtOAc/*n*-hexane as the eluent to afford the product.

2.3 Gram-scale synthesis of 3a




1a (3 mmol, 1 g)

2a (2.0 equiv)

3a (0.81g 60%)

In an oven-dried undivided three-necked bottle (250 mL) equipped with a stir bar, *N*-(phenylethynyl)-*N*-(*p*-tolyl) benzenesulfonamide **1a** (3 mmol, 1.005g), potassium thiocyanate **2a** (6 mmol), PIDA (4.5 mmol), acetic acid (4.5 mmol) and DCE (60 mL) were combined and added. The reaction mixture was reacted at 30 °C for 12 hours. When the reaction was finished, the reaction mixture was washed with water and extracted with CH₂Cl₂ (100 mL x 3). The organic layers were combined, dried over Na₂SO₄, and concentrated. The crude product was purified by column chromatography on silica gel using EtOAc/*n*-hexane (1:20) as eluent to afford the product **3a** in 60% yield.

2.4 General Procedure for the synthesis of product 7



A 15 mL tube was charged with substrate **6** (0.1 mmol, 1.0 equiv), **2a** (2.0 equiv), K₂S₂O₈ (1.5 equiv), CH₃COOH (1.5 equiv), Toluene (2 mL). The reaction mixture was reacted at 40 °C for 12 hours. After completing reaction, it was monitored with TLC. Then the reaction mixture was diluted with EtOAc (5 mL) and filtered through a pad of silica gel. The vial and silica gel were washed with an additional of EtOAc (5 mL). The filtrate was concentrated *in vacuo*, and the resulting residue was purified by flash column chromatography using EtOAc/*n*-hexane as the eluent to afford the product.

2.5 Characterization data

Table S1. Crystal data and structure refinement for **3d**.

Identification code	2104011479_0m
Empirical formula	C ₂₆ H ₂₃ N ₃ O ₂ S ₃
Formula weight	505.65

Temperature	173.0 K	
Wavelength	1.34139 Å	
Crystal system	Monoclinic	
Space group	C 1 2/c 1	
Unit cell dimensions	a = 20.0220(3) Å	a = 90°.
	b = 11.6268(2) Å	b = 107.0630(10)°.
	c = 22.3898(3) Å	g = 90°.
Volume	4982.74(13) Å ³	
Z	8	
Density (calculated)	1.348 Mg/m ³	
Absorption coefficient	1.920 mm ⁻¹	
F(000)	2112	
Crystal size	0.07 x 0.06 x 0.05 mm ³	
Theta range for data collection	3.870 to 54.954°.	
Index ranges	-24<=h<=24, -12<=k<=14, -27<=l<=26	
Reflections collected	20255	
Independent reflections	4675 [R(int) = 0.0314]	
Completeness to theta = 53.594°	98.4 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.7508 and 0.6144	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	4675 / 0 / 310	
Goodness-of-fit on F ²	1.031	
Final R indices [I>2sigma(I)]	R1 = 0.0334, wR2 = 0.0809	
R indices (all data)	R1 = 0.0386, wR2 = 0.0845	
Extinction coefficient	n/a	
Largest diff. peak and hole	0.475 and -0.396 e.Å ⁻³	




Figure 2-1 X-ray structure of **3d**


2.6 optimization of solvents

Table S2 Optimization of the reaction conditions^a

Entry	Variation from standard conditions	Yield (% 3a) ^b
1	DCM instead of DCE	trace
2	EtOAc instead of DCE	9
3	acetone instead of DCE	trace
4	H ₂ O ₂ instead of PIDA	14
5	O ₂ instead of PIDA	0

^aReaction conditions: **1a** (0.1 mmol, 1 equiv), **2a** (0.2 mmol), oxidant (0.15 mmol) and additive (0.15 mmol) in solvent (2 mL) at 30 °C for 12 h. ^bIsolated yield. ^cMeasured by ¹H NMR of the crude products. NR = no reaction.


(*E*)-*N*-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)-*N*-phenylbenzenesulfonamide (**3a**)



¹H NMR (400 MHz, CDCl₃) δ 7.61 – 7.57 (m, 1H), 7.56 – 7.52 (m, 2H), 7.48 – 7.41 (m, 5H), 7.38 (dd, *J* = 8.1, 1.6 Hz, 2H), 7.28 (t, *J* = 1.2 Hz, 0.5H), 7.24

(t, $J = 1.2$ Hz, 0.5H), 7.19 – 7.14 (m, 2H), 6.68 – 6.63 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.56, 138.07, 137.74, 133.74, 131.87, 130.45, 129.65, 129.33, 129.15, 128.89, 128.79, 128.18, 127.99, 127.77, 124.73, 107.31. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{22}\text{H}_{15}\text{N}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 450.0405, found: 450.0412.


(*E*)-*N*-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)-*N*-(*p*-tolyl) benzenesulfonamide (3b)



^1H NMR (400 MHz, CDCl_3) δ 7.61 – 7.57 (m, 1H), 7.55 – 7.52 (m, 2H), 7.48 – 7.40 (m, 7H), 6.96 (d, $J = 8.2$ Hz, 2H), 6.51 (d, $J = 8.4$ Hz, 2H), 2.29 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.45, 139.26, 137.75, 135.29,

133.68, 131.91, 130.44, 129.97, 129.72, 129.13, 128.77, 128.23, 127.84, 127.78, 124.74, 107.42, 21.16. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{23}\text{H}_{17}\text{N}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 464.0561, found: 464.0540.


(*E*)-*N*-(4-ethylphenyl)-*N*-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl) benzenesulfonamide (3c)



^1H NMR (400 MHz, CDCl_3) δ 7.59 (td, $J = 7.2, 1.3$ Hz, 1H), 7.56 – 7.52 (m, 2H), 7.48 – 7.39 (m, 7H), 6.99 (d, $J = 8.4$ Hz, 2H), 6.54 (d, $J = 8.4$ Hz, 2H), 2.59 (q, $J = 7.6$ Hz, 2H), 1.19 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 145.44, 140.48, 137.83, 135.43, 133.66, 131.93,

130.41, 129.73, 129.12, 128.74, 128.73, 128.24, 127.95, 127.77, 124.74, 107.40, 28.39, 15.17. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{24}\text{H}_{19}\text{N}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 478.0718, found: 478.0705.

(*E*)-*N*-(4-(*tert*-butyl)phenyl)-*N*-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)benzenesulfonamide (3d)




^1H NMR (400 MHz, CDCl_3) δ 7.61 – 7.57 (m, 1H), 7.55 (d, $J = 8.0$ Hz, 2H), 7.44 (dt, $J = 13.9, 6.8$ Hz, 7H), 7.18 (d, $J = 8.9$ Hz, 2H), 6.57 (d, $J = 8.6$ Hz, 2H), 1.26 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 152.34, 140.50, 137.85, 135.12, 133.63, 131.86, 130.37, 129.70, 129.11, 128.69,

128.20, 127.73, 127.59, 126.26, 124.57, 107.41, 34.67, 31.16. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{26}\text{H}_{23}\text{N}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 506.1031, found: 506.1022.


(E)-N-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)-N-(4-methoxyphenyl)

benzenesulfonamide (3e)




^1H NMR (400 MHz, CDCl_3) δ 7.61 – 7.57 (m, 1H), 7.55 – 7.52 (m, 2H), 7.49 – 7.42 (m, 7H), 6.68 – 6.63 (m, 2H), 6.53 – 6.49 (m, 2H), 3.75 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 159.88, 140.47, 137.67, 133.67, 131.98, 130.44, 130.29, 129.76, 129.66, 129.11, 128.79, 128.27, 127.50, 124.93, 114.41, 107.40, 55.45. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{23}\text{H}_{17}\text{N}_3\text{O}_3\text{S}_3$ $[\text{M}+\text{H}]^+$: 480.0510, found: 480.0503.

(E)-N-(4-fluorophenyl)-N-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)benzenesulfonamide (3f)



^1H NMR (400 MHz, CDCl_3) δ 7.63 – 7.59 (m, 1H), 7.55 – 7.52 (m, 2H), 7.49 – 7.43 (m, 5H), 7.41 – 7.37 (m, 2H), 6.88 – 6.82 (m, 2H), 6.61 – 6.55 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 162.43 (d, $J=251.49$ Hz), 140.70, 137.47, 133.92, 133.82 (d, $J= 3.03$ Hz), 131.84, 130.58, 130.9 (d, $J= 9.09$ Hz), 129.64, 129.26, 128.90, 128.19, 128.07, 124.66, 116.33 (d, $J= 22.22$ Hz), 107.23. ^{19}F NMR (376 MHz, CDCl_3) δ -110.58 (s, 1F). HRMS (ESI-TOF) m/z Calcd for $\text{C}_{22}\text{H}_{14}\text{FN}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 468.0310, found: 468.0301.


(E)-N-(4-chlorophenyl)-N-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)benzenesulfonamide (3g)



^1H NMR (400 MHz, CDCl_3) δ 7.61 (t, $J = 7.4$ Hz, 1H), 7.56 (d, $J = 8.3$ Hz, 2H), 7.46 (dt, $J = 6.3, 3.4$ Hz, 5H), 7.37 (dd, $J = 7.7, 1.9$ Hz, 2H), 7.14 (d, $J = 8.7$ Hz, 2H), 6.57 (d, $J = 8.7$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.76, 137.49, 136.49, 134.94, 133.93, 131.74, 130.57, 129.56, 129.53, 129.28, 128.98, 128.88, 128.27, 128.12, 124.48, 107.13. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{22}\text{H}_{14}\text{ClN}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 484.0015, found: 484.0024.


(E)-N-(4-bromophenyl)-N-(1-isothiocyanato-2-phenyl-2-

thiocyanatovinyl)benzenesulfonamide (3h)




^1H NMR (400 MHz, CDCl_3) δ 7.63 – 7.59 (m, 1H), 7.57 – 7.54 (m, 2H), 7.48 – 7.43 (m, 5H), 7.37 (dd, $J = 7.9, 1.7$ Hz, 2H), 7.31 – 7.27 (m, 2H), 6.54 – 6.49 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.79, 137.50, 137.06, 133.94, 132.54, 131.74, 130.57, 129.55, 129.29, 129.19, 128.88, 128.31, 128.11, 124.43, 123.03, 107.11. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{22}\text{H}_{14}\text{BrN}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 527.9510, found: 527.9499.

methyl(*E*)-4-(*N*-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)phenylsulfonamido)benzoate (3i)




^1H NMR (400 MHz, CDCl_3) δ 7.88 – 7.78 (m, 2H), 7.65 – 7.54 (m, 3H), 7.42 (dt, $J = 9.5, 7.1$ Hz, 5H), 7.31 (d, $J = 6.6$ Hz, 2H), 6.80 (d, $J = 8.7$ Hz, 2H), 3.89 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 165.89, 142.20, 137.56, 134.00, 131.62, 130.65, 130.54, 129.75, 129.40, 129.30, 128.86, 127.99, 126.21, 124.38, 107.06, 52.39. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{24}\text{H}_{17}\text{N}_3\text{O}_4\text{S}_3$ $[\text{M}+\text{H}]^+$: 508.0459, found: 508.0449.

(*E*)-*N*-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)-*N*-(*o*-tolyl) benzenesulfonamide (3j)



^1H NMR (400 MHz, CDCl_3) δ 7.65 – 7.59 (m, 3H), 7.49 – 7.38 (m, 5H), 7.33 – 7.29 (m, 2H), 7.11 (td, $J = 7.5, 1.3$ Hz, 1H), 7.03 (d, $J = 7.9$ Hz, 1H), 6.80 (td, $J = 7.7, 1.8$ Hz, 1H), 6.36 (dd, $J = 8.1, 1.3$ Hz, 1H), 1.56 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 138.76, 137.81, 137.44, 136.74, 133.86, 132.15, 131.70, 130.52, 130.12, 129.92, 129.35, 129.14, 129.02, 128.28, 126.92, 126.11, 125.44, 107.49, 17.99. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{24}\text{H}_{17}\text{N}_3\text{O}_4\text{S}_3$ $[\text{M}+\text{H}]^+$: 464.0561, found: 464.0557.

(*E*)-*N*-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)-*N*-(*m*-tolyl) benzenesulfonamide (3k)




^1H NMR (400 MHz, CDCl_3) δ 7.62 – 7.55 (m, 3H), 7.48 – 7.42 (m, 5H), 7.37 (dd, $J = 7.8, 1.9$ Hz, 2H), 7.05 (d, $J = 6.7$ Hz, 2H), 6.46 – 6.35 (m, 2H), 2.16 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.59, 139.40, 137.85, 138.84, 133.66, 131.92, 130.36, 129.69, 129.64, 129.07, 128.96, 128.80, 128.71,

128.20, 127.63, 124.83, 124.61, 107.34, 21.18. HRMS (ESI-TOF) m/z Calcd for $C_{24}H_{17}N_3O_4S_3$ $[M+H]^+$: 464.0561, found: 464.0569.


(E)-N-(3-chlorophenyl)-N-(1-isothiocyanato-2-phenyl-2-thiocyanatovinyl)

benzenesulfonamide (3l)



1H NMR (400 MHz, $CDCl_3$) δ 7.62 (t, $J = 7.4$ Hz, 1H), 7.58 (d, $J = 7.5$ Hz, 2H), 7.47 (dq, $J = 8.0, 3.4$ Hz, 5H), 7.34 (d, $J = 6.1$ Hz, 2H), 7.24 (d, $J = 7.1$ Hz, 1H), 7.11 (t, $J = 8.4$ Hz, 1H), 6.60 – 6.56 (m, 2H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 141.04, 139.06, 137.55, 134.72, 134.02, 131.66, 130.65, 130.15, 129.51, 129.32, 129.03, 128.90, 128.36, 128.12, 128.03, 125.51, 124.38, 107.13. HRMS (ESI-TOF) m/z Calcd for $C_{22}H_{14}ClN_3O_2S_3$ $[M+H]^+$: 484.0015, found: 484.0009.


(E)-N-(1-isothiocyanato-2-thiocyanato-2-(p-tolyl) vinyl)-N-(p-tolyl) benzenesulfonamide (5a)



1H NMR (400 MHz, $CDCl_3$) δ 7.61 – 7.53 (m, 3H), 7.43 (t, $J = 7.8$ Hz, 2H), 7.31 (d, $J = 8.1$ Hz, 2H), 7.26 (d, $J = 3.0$ Hz, 2H), 6.97 (d, $J = 8.1$ Hz, 2H), 6.54 (d, $J = 8.3$ Hz, 2H), 2.43 (s, 3H), 2.29 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 140.74, 140.23, 139.22, 137.85, 135.35, 133.61, 129.96, 129.61, 129.45, 129.10, 128.91, 128.41, 128.24, 127.89, 124.11, 107.55, 21.59, 21.14. HRMS (ESI-TOF) m/z Calcd for $C_{24}H_{19}N_3O_2S_3$ $[M+H]^+$: 478.0718, found: 478.0713.

(E)-N-(1-isothiocyanato-2-(4-methoxyphenyl)-2-thiocyanatovinyl)-N-(p-tolyl)


benzenesulfonamide (5b)



1H NMR (400 MHz, $CDCl_3$) δ 7.62 – 7.55 (m, 3H), 7.47 – 7.42 (m, 2H), 7.40 – 7.35 (m, 2H), 7.00 – 6.95 (m, 4H), 6.57 – 6.52 (m, 2H), 3.88 (s, 3H), 2.29 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 161.15, 140.12, 139.21, 137.86, 135.39, 133.63, 131.33, 129.98, 129.13, 128.29, 128.23, 127.82, 123.92, 123.89, 114.18, 107.65, 55.42, 21.14. HRMS (ESI-TOF) m/z Calcd for $C_{24}H_{19}N_3O_3S_3$ $[M+H]^+$: 494.0667, found: 494.0655.


(E)-N-(2-(4-ethylphenyl)-1-isothiocyanato-2-thiocyanatovinyl)-N-(p-tolyl)

benzenesulfonamide (5c)




^1H NMR (400 MHz, CDCl_3) δ 7.58 (t, $J = 7.4$ Hz, 1H), 7.56 – 7.48 (m, 2H), 7.45 – 7.38 (m, 2H), 7.37 – 7.26 (m, 4H), 6.96 (d, $J = 8.2$ Hz, 2H), 6.62 – 6.45 (m, 2H), 2.73 (q, $J = 7.6$ Hz, 2H), 2.29 (s, 3H), 1.30 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 146.97, 140.22, 139.16, 137.86, 135.33, 133.59, 130.45, 129.90, 129.68, 129.13, 129.07, 128.21, 128.14, 127.86, 124.32, 107.54, 28.80, 21.12, 15.31. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 492.0874, found: 492.0866.

(E)-N-(2-(4-(tert-butyl)phenyl)-1-isothiocyanato-2-thiocyanatovinyl)-N-(p-tolyl) benzenesulfonamide (5d)




^1H NMR (400 MHz, CDCl_3) δ 7.58 (t, $J = 7.4$ Hz, 1H), 7.55 – 7.52 (m, 2H), 7.46 – 7.40 (m, 4H), 7.35 – 7.31 (m, 2H), 6.93 (d, $J = 8.3$ Hz, 2H), 6.51 – 6.47 (m, 2H), 2.28 (s, 3H), 1.37 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 153.90, 140.26, 139.12, 137.90, 135.34, 133.60, 129.84, 129.44, 129.08, 128.97, 128.21, 127.85, 127.66, 125.63, 124.71, 107.59, 34.97, 31.26, 21.13. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{27}\text{H}_{25}\text{N}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 520.1187, found: 520.1168.

(E)-N-(2-(4-fluorophenyl)-1-isothiocyanato-2-thiocyanatovinyl)-N-(p-tolyl) benzenesulfonamide (5e)



^1H NMR (400 MHz, CDCl_3) δ 7.60 (t, $J = 7.4$ Hz, 1H), 7.56 (d, $J = 7.1$ Hz, 2H), 7.48 – 7.39 (m, 4H), 7.15 (t, $J = 8.6$ Hz, 2H), 6.99 (d, $J = 8.2$ Hz, 2H), 6.53 (d, $J = 8.3$ Hz, 2H), 2.30 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 163.70 (d, $J = 252.50$ Hz), 140.61, 139.35, 137.69, 135.29, 133.76, 131.94 (d, $J = 8.08$ Hz), 130.06, 129.17, 128.20, 127.92 (d, $J = 2.02$ Hz), 127.62, 126.69, 125.21, 116.09 (d, $J = 23.23$ Hz), 107.27, 21.13. ^{19}F NMR (376 MHz, CDCl_3) δ -108.78 (s, 1F). HRMS (ESI-TOF) m/z Calcd for $\text{C}_{23}\text{H}_{16}\text{FN}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 482.0467, fund: 482.0474.

(E)-N-(2-(4-chlorophenyl)-1-isothiocyanato-2-thiocyanatovinyl)-N-(p-tolyl) benzenesulfonamide (5f)




^1H NMR (400 MHz, CDCl_3) δ 7.61 (t, $J = 7.4$ Hz, 1H), 7.55 (d, $J = 7.1$

Hz, 2H), 7.47 – 7.42 (m, 4H), 7.36 (d, $J = 8.5$ Hz, 2H), 7.00 (d, $J = 8.1$ Hz, 2H), 6.55 (d, $J = 8.3$ Hz, 2H), 2.30 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.66, 139.41, 137.63, 136.65, 135.25, 133.79, 131.12, 130.40, 130.11, 129.18, 129.16, 128.20, 127.62, 126.39, 125.44, 107.20, 21.14. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{23}\text{H}_{16}\text{ClN}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 498.0171, found: 498.0169.

(*E*)-*N*-(2-(4-bromophenyl)-1-isothiocyanato-2-thiocyanatovinyl)-*N*-(*p*-tolyl)benzenesulfonamide (5g)

benzenesulfonamide (5g)




^1H NMR (400 MHz, CDCl_3) δ 7.63 – 7.58 (m, 3H), 7.56 – 7.52 (m, 2H), 7.48 – 7.42 (m, 2H), 7.31 – 7.27 (m, 2H), 7.00 (d, $J = 8.3$ Hz, 2H), 6.58 – 6.53 (m, 2H), 2.30 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.67, 139.42, 137.62, 135.23, 133.79, 132.11, 131.30, 130.91,

130.12, 129.18, 128.20, 127.62, 126.38, 125.43, 125.00, 107.19, 21.14. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{23}\text{H}_{16}\text{BrN}_3\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 541.9666, found: 541.9659.

(*E*)-*N*-(2-(4-cyanophenyl)-1-isothiocyanato-2-thiocyanatovinyl)-*N*-(*p*-tolyl)benzenesulfonamide (5h)

benzenesulfonamide (5h)




^1H NMR (400 MHz, CDCl_3) δ 8.31 (d, $J = 8.9$ Hz, 2H), 7.64 – 7.58 (m, 1H), 7.58 – 7.55 (m, 2H), 7.51 – 7.40 (m, 4H), 6.94 (d, $J = 8.1$ Hz, 2H), 6.57 (d, $J = 8.4$ Hz, 2H), 2.28 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 148.86, 145.42, 139.49, 138.96, 136.74, 134.96, 134.23, 130.29,

130.15, 129.12, 128.26, 126.95, 126.28, 124.15, 106.89, 105.87, 21.05. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{24}\text{H}_{16}\text{N}_4\text{O}_2\text{S}_3$ $[\text{M}+\text{H}]^+$: 489.0514, found: 489.0511.

methyl(*E*)-4-(2-isothiocyanato-1-thiocyanato-2-(*N*-(*p*-tolyl)phenylsulfonamido)vinyl)benzoate (5i)

phenylsulfonamido)vinyl)benzoate (5i)




^1H NMR (400 MHz, CDCl_3) δ 8.13 (dd, $J = 8.6, 2.0$ Hz, 2H), 7.60 (t, $J = 7.4$ Hz, 1H), 7.55 (d, $J = 7.1$ Hz, 2H), 7.50 (d, $J = 8.5$ Hz, 2H), 7.47 – 7.41 (m, 2H), 6.97 (d, $J = 8.0$ Hz, 2H), 6.52 (d, $J = 8.4$ Hz, 2H), 3.97 (s, 3H), 2.29 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.26, 140.78, 139.41, 137.57, 136.42, 135.25, 133.80, 131.66, 130.10, 129.96, 129.88,

129.17, 128.21, 127.56, 126.21, 125.94, 107.04, 52.45, 21.13. HRMS (ESI-TOF) m/z Calcd for

C₂₅H₁₉N₃O₄S₃ [M+H]⁺: 522.0616, found: 522.0609.


(E)-N-(1-isothiocyanato-2-thiocyanato-2-(*m*-tolyl)vinyl)-N-(*p*-tolyl)benzenesulfonamide (5j)



¹H NMR (400 MHz, CDCl₃) δ 7.60 – 7.53 (m, 3H), 7.45 – 7.40 (m, 2H), 7.33 (t, *J* = 7.8 Hz, 1H), 7.28 (s, 1H), 7.20 – 7.17 (m, 2H), 6.97 (d, *J* = 8.6 Hz, 2H), 6.54 – 6.50 (m, 2H), 2.38 (s, 3H), 2.29 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 140.41, 139.18, 138.48, 137.85, 135.42, 133.61,

131.75, 131.15, 130.20, 129.89, 129.07, 128.62, 128.21, 128.01, 127.88, 126.73, 124.52, 107.47, 21.37, 21.13. HRMS (ESI-TOF) *m/z* Calcd for C₂₄H₁₉N₃O₂S₃ [M+H]⁺: 478.0718, found: 478.0722.


(E)-N-(2-(3-fluorophenyl)-1-isothiocyanato-2-thiocyanatovinyl)-N-(*p*-tolyl)benzenesulfonamide (5k)



¹H NMR (400 MHz, CDCl₃) δ 7.62 – 7.58 (m, 1H), 7.57 – 7.50 (m, 2H), 7.44 (ddt, *J* = 9.9, 4.5, 3.0 Hz, 3H), 7.24 (ddd, *J* = 7.7, 1.7, 1.0 Hz, 1H), 7.17 (tdd, *J* = 8.5, 2.6, 1.0 Hz, 1H), 7.11 – 7.05 (m, 1H), 6.99 (d, *J* = 8.7 Hz, 2H), 6.60 – 6.51 (m, 2H), 2.30 (s, 3H). ¹³C NMR (100 MHz,

CDCl₃) δ 162.41 (d, *J* = 249.47 Hz), 140.85, 139.44, 137.63, 136.17, 135.27, 133.90, 133.80, 130.52 (d, *J* = 9.09 Hz), 130.09, 129.17, 128.21, 127.65, 125.81 (d, *J* = 4.04 Hz), 125.70 (d, *J* = 3.03 Hz), 117.48 (d, *J* = 20.2 Hz), 116.84 (d, *J* = 23.23 Hz), 107.10, 21.14. ¹⁹F NMR (376 MHz, CDCl₃) δ -111.02 (s, 1F). HRMS (ESI-TOF) *m/z* Calcd for C₂₃H₁₆FN₃O₂S₃ [M+H]⁺: 482.0467, found: 482.0459.

(E)-N-(2-(2-fluorophenyl)-1-isothiocyanato-2-thiocyanatovinyl)-N-(*p*-tolyl)benzenesulfonamide (5l)




¹H NMR (400 MHz, CDCl₃) δ 7.61 – 7.54 (m, 3H), 7.53 – 7.46 (m, 2H), 7.46 – 7.41 (m, 2H), 7.32 – 7.27 (m, 1H), 7.08 (t, *J* = 8.5 Hz, 1H), 6.98 (d, *J* = 8.4 Hz, 2H), 6.55 (d, *J* = 8.4 Hz, 2H), 2.30 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 159.62 (d, *J* = 252.50 Hz), 141.05, 139.31, 137.75, 135.04,

133.72, 132.75 (d, *J* = 8.08 Hz), 131.95, 129.98, 129.13, 128.18, 127.72, 126.72, 124.64 (d, *J* = 3.03 Hz), 121.97, 119.81 (d, *J* = 14.14 Hz), 115.98 (d, *J* = 20.2 Hz), 107.13, 21.16. ¹⁹F NMR (376 MHz,


CDCl₃) δ -110.23 (s, 1F). HRMS (ESI-TOF) m/z Calcd for C₂₃H₁₆FN₃O₂S₃ [M+H]⁺: 482.0467, found: 482.0471.

5-methyl-3-phenyl-1-(phenylsulfonyl)-2-thiocyanatoindoline (7a)




¹H NMR (400 MHz, CDCl₃) δ 7.60 (t, *J* = 7.4 Hz, 1H), 7.53 (d, *J* = 7.3 Hz, 2H), 7.47 – 7.42 (m, 5H), 7.25 (d, *J* = 2.8 Hz, 1H), 7.03 (d, *J* = 8.2 Hz, 2H), 6.83 (d, *J* = 10.5 Hz, 1H), 6.52 (d, *J* = 7.9 Hz, 2H), 4.03 (d, *J* = 10.5 Hz, 1H), 2.33 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 141.55, 140.41, 137.57, 133.68, 133.08, 130.85, 130.45, 130.02, 129.92, 129.42, 129.14, 128.36, 128.20, 109.51, 72.35, 56.08, 21.29. HRMS (ESI-TOF) m/z Calcd for C₂₂H₁₈O₂S₂N₂ [M+H]⁺: 406.0810, found: 406.0812.

5-fluoro-3-phenyl-1-(phenylsulfonyl)-2-thiocyanatoindoline (7b)




¹H NMR (400 MHz, CDCl₃) δ 7.63 (t, *J* = 7.0 Hz, 2H), 7.56 – 7.53 (m, 2H), 7.52 – 7.45 (m, 6H), 6.97 – 6.90 (m, 2H), 6.84 (d, *J* = 10.5 Hz, 1H), 6.62 (s, 1H), 3.99 (d, *J* = 10.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 163.14 (d, *J* = 252.5 Hz), 142.45, 137.22, 133.88, 133.06 (d, *J* = 9.09 Hz), 131.51 (d, *J* = 269.67 Hz), 129.66, 129.52, 129.24, 128.76, 128.32, 128.26, 128.18, 116.30 (d, *J* = 23.23 Hz), 109.27, 72.35, 56.14. ¹⁹F NMR (376 MHz, CDCl₃) δ -109.21 (s, 1F). HRMS (ESI-TOF) m/z Calcd for C₂₁H₁₅O₂S₂N₂F [M+H]⁺: 411.0632, found: 411.0629.

5-(tert-butyl)-3-phenyl-1-(phenylsulfonyl)-2-thiocyanatoindoline (7c)



¹H NMR (400 MHz, CDCl₃) δ 7.61 (t, *J* = 7.4 Hz, 1H), 7.55 (d, *J* = 7.3 Hz, 2H), 7.47 (dd, *J* = 6.6, 2.4 Hz, 5H), 7.27 – 7.24 (m, 3H), 6.82 (d, *J* = 10.5 Hz, 1H), 6.58 (d, *J* = 8.4 Hz, 2H), 4.06 (d, *J* = 10.5 Hz, 1H), 1.30 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 153.45, 141.29, 137.71, 133.63, 133.08, 130.56, 130.39, 130.01, 129.41, 129.14, 128.37, 128.18, 126.20, 109.54, 72.42, 56.02, 34.85, 31.24. HRMS (ESI-TOF) m/z Calcd for C₂₅H₂₄O₂S₂N₂ [M+H]⁺: 448.1279, found: 448.1277.


5-ethyl-3-phenyl-1-(phenylsulfonyl)-2-thiocyanatoindoline (7d)



^1H NMR (400 MHz, CDCl_3) δ 7.61 (t, $J = 7.3$ Hz, 1H), 7.54 (d, $J = 7.4$ Hz, 2H), 7.48 – 7.43 (m, 5H), 7.26 (d, $J = 2.8$ Hz, 1H), 7.06 (d, $J = 8.3$ Hz, 2H), 6.82 (d, $J = 10.5$ Hz, 1H), 6.55 (d, $J = 8.1$ Hz, 2H), 4.05 (d, $J = 10.5$ Hz, 1H), 2.64 (q, $J = 7.6$ Hz, 2H), 1.23 (t, $J = 7.6$ Hz, 3H). ^{13}C

NMR (100 MHz, CDCl_3) δ 146.50, 141.51, 137.66, 133.62, 133.08, 130.92, 130.63, 130.01, 129.40, 129.11, 128.64, 128.36, 128.20, 109.46, 72.41, 56.10, 28.49, 15.10. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{23}\text{H}_{20}\text{O}_2\text{S}_2\text{N}_2$ $[\text{M}+\text{H}]^+$: 420.0966, found: 420.0965.


methyl 3-phenyl-1-(phenylsulfonyl)-2-thiocyanatoindoline-5-carboxylate (7e)



^1H NMR (400 MHz, CDCl_3) δ 7.91 (d, $J = 8.7$ Hz, 2H), 7.64 (t, $J = 7.3$ Hz, 1H), 7.56 – 7.51 (m, 2H), 7.50 – 7.45 (m, 4H), 7.20 (dd, $J = 7.3$, 1.8 Hz, 2H), 6.85 (d, $J = 10.6$ Hz, 1H), 6.74 (d, $J = 8.4$ Hz, 2H), 4.00 (d, $J = 10.6$ Hz, 1H), 3.93 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ

165.89, 142.80, 137.78, 137.24, 133.97, 132.72, 131.42, 130.86, 130.38, 130.19, 129.51, 129.30, 128.21, 128.11, 109.22, 72.38, 56.16, 52.56. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{23}\text{H}_{18}\text{O}_4\text{S}_2\text{N}_2$ $[\text{M}+\text{H}]^+$: 450.0708, found: 450.0778.


6-methyl-3-phenyl-1-(phenylsulfonyl)-2-thiocyanatoindoline (7f)



^1H NMR (400 MHz, CDCl_3) δ 7.62 (t, $J = 7.4$ Hz, 1H), 7.55 (d, $J = 7.3$ Hz, 2H), 7.46 (p, $J = 4.8$, 4.1 Hz, 5H), 7.25 – 7.23 (m, 1H), 7.18 (d, $J = 7.6$ Hz, 1H), 7.11 (t, $J = 7.7$ Hz, 1H), 6.80 (d, $J = 10.5$ Hz, 1H), 6.40 (d, $J = 37.0$ Hz, 2H), 4.02 (d, $J = 10.5$ Hz, 1H), 2.20 (s, 3H). ^{13}C NMR (100 MHz,

CDCl_3) δ 141.59, 139.31, 137.58, 133.68, 133.10, 132.20, 130.79, 130.02, 129.34, 129.08, 128.88, 128.36, 128.22, 127.54, 109.45, 72.35, 56.12, 21.21. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{22}\text{H}_{18}\text{O}_2\text{S}_2\text{N}_2$ $[\text{M}+\text{H}]^+$: 406.0810, found: 406.0812.


1-(naphthalen-1-ylsulfonyl)-3-phenyl-2-thiocyanatoindoline (7g)



^1H NMR (400 MHz, CDCl_3) δ 8.15 (s, 1H), 7.93 – 7.85 (m, 3H), 7.66 (t, $J = 7.5$ Hz, 1H), 7.59 (t, $J = 7.5$ Hz, 1H), 7.47 – 7.43 (m, 4H), 7.36 (t, $J = 7.4$ Hz,


1H), 7.26 (dd, $J = 5.7, 2.3$ Hz, 1H), 7.21 (t, $J = 7.9$ Hz, 2H), 6.93 (d, $J = 10.5$ Hz, 1H), 6.67 (d, $J = 7.7$ Hz, 2H), 4.04 (d, $J = 10.5$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 142.14, 135.11, 134.31, 133.33, 132.94, 131.95, 131.07, 129.97, 129.89, 129.46, 129.34, 129.29, 129.19, 129.15, 128.25, 127.85, 127.62, 109.36, 72.38, 56.00. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{25}\text{H}_{18}\text{O}_2\text{S}_2\text{N}_2$ $[\text{M}+\text{H}]^+$: 442.0810, found: 442.0811.

3-phenyl-2-thiocyanato-1-tosylindoline (7h)



^1H NMR (400 MHz, CDCl_3) δ 7.47 – 7.43 (m, 3H), 7.41 (d, $J = 8.3$ Hz, 2H), 7.36 (d, $J = 7.5$ Hz, 1H), 7.26 – 7.21 (m, 6H), 6.84 (d, $J = 10.5$ Hz, 1H), 6.66 (d, $J = 7.6$ Hz, 2H), 4.03 (d, $J = 10.5$ Hz, 1H), 2.42 (s, 3H). ^{13}C NMR (100 MHz, Chloroform- d) δ 144.78, 131.10, 130.01, 129.98, 129.75, 129.40, 129.20, 128.33, 128.21, 109.46, 72.36, 56.15, 21.71. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{22}\text{H}_{19}\text{O}_2\text{S}_2\text{N}_2$ $[\text{M}+\text{H}]^+$: 407.0882, found: 407.0881.

3-phenyl-1-(phenylsulfonyl)-2-thiocyanatoindoline (7i)




^1H NMR (400 MHz, CDCl_3) δ 7.61 (t, $J = 7.4$ Hz, 1H), 7.55 – 7.51 (m, 2H), 7.48 – 7.42 (m, 5H), 7.37 (t, $J = 7.4$ Hz, 1H), 7.25 – 7.21 (m, 3H), 6.85 (d, $J = 10.5$ Hz, 1H), 6.65 (d, $J = 7.6$ Hz, 2H), 4.03 (d, $J = 10.5$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform- d) δ 137.48, 133.74, 133.39, 133.00, 131.08, 130.08, 130.07, 129.43, 129.25, 129.16, 128.32, 128.19, 72.36, 56.10. HRMS (ESI-TOF) m/z Calcd for $\text{C}_{21}\text{H}_{17}\text{O}_2\text{S}_2\text{N}_2$ $[\text{M}+\text{H}]^+$: 393.0726, found: 393.0723.


3. References

1. F. Pan, X.-L. Li, X.-M. Chen, C. Shu, P.-P. Ruan, C.-H. Shen, X. Lu and L.-W. Ye, *ACS Catalysis*, 2016, **6**, 6055-6062.
2. Z. Zeng, H. Jin, J. Xie, B. Tian, M. Rudolph, F. Rominger and A. S. Hashmi, *Org Lett*, 2017, **19**, 1020-1023.
3. L. Zhu, Y. Yu, Z. Mao and X. Huang, *Org Lett*, 2015, **17**, 30-33.
4. L. Liao, H. Zhang and X. Zhao, *ACS Catalysis*, 2018, **8**, 6745-6750.


4. ^1H NMR, ^{19}F NMR and ^{13}C NMR spectra




¹H NMR Spectrum of Compound 3a (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 3a (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **3b** (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **3b** (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound 3c (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 3c (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound 3d (400 MHz, CDCl₃)





¹³C NMR Spectrum of Compound 3d (100 MHz, CDCl₃)






¹H NMR Spectrum of Compound 3e (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 3e (100 MHz, CDCl₃)









¹³C NMR Spectrum of Compound 3g (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound 3h (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 3h (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound 3i (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **3i** (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **3j** (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **3j** (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **3k** (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **3k** (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **3l** (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **31** (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **5a** (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 5a (100 MHz, CDCl₃)





¹H NMR Spectrum of Compound 5b (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **5b** (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **5c** (400 MHz, CDCl₃)




¹H NMR Spectrum of Compound 5d (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **5d** (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **5e** (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 5e (100 MHz, CDCl₃)




¹⁹F NMR Spectrum of Compound 5e (376 MHz, CDCl₃)




¹H NMR Spectrum of Compound 5f (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 5f (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **5g** (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **5g** (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **5h (400 MHz, CDCl₃)**




¹³C NMR Spectrum of Compound **5h (100 MHz, CDCl₃)**




¹H NMR Spectrum of Compound **5i (400 MHz, CDCl₃)**




¹³C NMR Spectrum of Compound **5i (100 MHz, CDCl₃)**




¹H NMR Spectrum of Compound **5j (400 MHz, CDCl₃)**




¹³C NMR Spectrum of Compound **5j (100 MHz, CDCl₃)**




¹H NMR Spectrum of Compound **5k** (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **5k** (100 MHz, CDCl₃)




¹⁹F NMR Spectrum of Compound **5k** (376 MHz, CDCl₃)




¹H NMR Spectrum of Compound **5l** (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **51** (100 MHz, CDCl₃)




¹⁹F NMR Spectrum of Compound **51** (376 MHz, CDCl₃)




¹H NMR Spectrum of Compound 7a (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 7a (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **7b** (400 MHz, CDCl₃)




¹⁹F NMR Spectrum of Compound **7b** (376 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 7b (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound 7c (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 7c (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound 7d (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 7d (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound 7e (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 7e (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound 7f (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound 7f (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound 7g (400 MHz, CDCl₃)




¹³C NMR Spectrum of Compound **7g** (100 MHz, CDCl₃)




¹H NMR Spectrum of Compound **7h** (400 MHz, CDCl₃)



¹³C NMR Spectrum of Compound 7h (100 MHz, CDCl₃)



¹H NMR Spectrum of Compound 7i (400 MHz, CDCl₃)



¹³C NMR Spectrum of Compound 7i (100 MHz, CDCl₃)